← Back to Clinical Trials
Recruiting NCT06835374

NCT06835374 Comparative Assessment of Esophagitis in Cases With and Without Esophageal Motility Disorders: A Prospective Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06835374
Status Recruiting
Phase
Sponsor Asian Institute of Gastroenterology, India
Condition Esophageal Diseases
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2024-05-11
Primary Completion 2026-05-28

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Per oral endoscopy myotomy (Per oral endoscopy myotomy)Endoscopy procedure

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2024-05-11 with a primary completion date of 2026-05-28.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Achalasia is a neuro-degenerative disorder marked by changes in the peristalsis of the esophagus and the lack of relaxation in the lower esophageal sphincter (LES), thought to be due to damage to the myenteric plexus with an unknown cause.1 Per-oral endoscopic myotomy (POEM) is an established endoscopic treatment modality for achalasia. Leading gastrointestinal (GI) societies endorse POEM as one of the primary treatment option for achalasia.This study aims to characterize and compare the morphological characteristics of reflux related erosions after the POEM procedures versus those in cases without esophageal motility disorders. Data collection 1. Demographic characteristics: Age, gender, type of achalasia 2. Manometry findings (pre and post POEM): integrated relaxation pressure, lower esophageal sphincter pressure 3. Comorbidities 4. Medications 5. Eckardt score: before procedure and 3-months after Procedure 6. POEM procedure details: length of esophageal and gastric myotomy, adverse events, length of hospital stay 7. Evaluation at 3-months Symptom: standardized questionnaire (GERDQ) Endoscopy: grade of esophagitis Erosions vs ulcers Dimension of erosions Anatomical location (according to clock)

Eligibility Criteria

Inclusion Criteria: 1. Age≥18y, 2. confirmed diagnosis of Achalasia, 3. No contraindication to POEM, 4. erosive esophagitis on endoscopy Exclusion Criteria: 1. Non-esophageal esophageal motility disorders, 2. Treatment other than POEM, 3. current PPI use before assessment for GERD

Contact & Investigator

Central Contact

Rajesh Goud Mr Maragoni, M.Pharm, MBA

✉ rajeshgoud761@gmail.com

📞 04023378888

Principal Investigator

Zaheer Nabi Dr Mohammed, MBBS MD

PRINCIPAL INVESTIGATOR

AIG Hospitals

Frequently Asked Questions

Who can join the NCT06835374 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Esophageal Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06835374 currently recruiting?

Yes, NCT06835374 is actively recruiting participants. Contact the research team at rajeshgoud761@gmail.com for enrollment information.

Where is the NCT06835374 trial being conducted?

This trial is being conducted at Hyderabad, India.

Who is sponsoring the NCT06835374 clinical trial?

NCT06835374 is sponsored by Asian Institute of Gastroenterology, India. The principal investigator is Zaheer Nabi Dr Mohammed, MBBS MD at AIG Hospitals. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology